How much does Brivaracetam cost? How does the price compare to other similar medications?

Brivaracetam (Brivaracetam) is an antiepileptic drug used to treat epilepsy, often as add-on therapy to control partial seizures. The price of Brivaracetam varies in different countries and regions and is affected by various factors such as manufacturers, import costs, and market demand. Although Brivaracetam is not yet on the market in China, its price in overseas markets, especially in Europe and the United States, has a clear reference.

According to current market information, the overseas price of the original research version of Brivaracetam is approximately 4000 multiple yuan, and the specification is 50mg*60 tablets. This price usually reflects factors such as import charges, patent protection, and production costs of the drug, making it relatively high for domestic patients. However, given the efficacy of brivaracetam and its effectiveness as a treatment for partial epilepsy, it remains one of the drugs of choice for many patients and physicians, especially when conventional treatments fail to effectively control the condition.

Brivaracetam's price is moderately high compared to other similar drugs. Common anti-epileptic drugs such as lamotrigine and topiramate are usually relatively cheap in the domestic market, usually ranging from a few hundred yuan to more than a thousand yuan. Compared with these drugs, brivaracetam is more expensive, but its therapeutic effect and ease of use make it still have market demand among specific patient groups. Particularly in the treatment of drug-resistant epilepsy, brivaracetam may become an important option.

For domestic patients, since Brivaracetam is not yet on the market, patients can currently only obtain the drug through overseas purchasing or purchasing overseas. However, this approach is not only more expensive, but also has certain limitations in terms of time and cost. Therefore, although the efficacy of brivaracetam is relatively significant, its high price may cause some patients to face financial pressure. As relevant domestic approval procedures advance, more alternatives or locally produced brivaracetam may be launched in the future, helping to reduce treatment costs and improve drug accessibility.

Reference materials:https://www.briviact.com/